We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Commentary · October 09, 2020

FDA Assessment of the Safety of Glucose-Lowering Drugs

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Assessing the Safety of Glucose-Lowering Drugs — A New Focus for the FDA
N. Engl. J. Med 2020 Sep 24;383(13)1199-1202, WH Chong, LB Yanoff, E Andraca-Carrera, M Thanh Hai

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading